The Global Initiative in Asthma (GINA) asthma challenge: reducing asthma hospitalizations.

J Mark FitzGerald,
Eric Bateman,
Suzanne Hurd,
Louis-Philippe Boulet,
Tari Haahtela,
Alvaro A. Cruz,
Mark L Levy,

Key words: chronic disease, asthma, respiratory health, hospitalizations

Address for correspondence and reprints:
J Mark FitzGerald
Institute for Heart and Lung health
The Lung Centre, 7th Floor
Gordon and Leslie Diamond Health Care Centre,
2775 Laurel Street,
Vancouver, B.C.
V5Z 1M9
Phone: 604 875 4122
Email:mark.fitzgerald@vch.ca
For several decades, global health agendas have been dominated by the burden of endemic infections like malaria and epidemics caused by respiratory viruses, HIV and the resurgence of tuberculosis (TB). Recently, under the leadership of the WHO and other agencies(1), attention has been directed towards the growing morbidity and mortality attributable to chronic diseases – the predominant ones being cardiovascular, respiratory, metabolic, and neoplastic – as well as the fact that in many countries, the strategies and resources to address these major public health challenges are either non-existent or rudimentary.(2) In 2005, it was estimated that 35 million of all worldwide deaths were attributable to chronic diseases. This is twice the number of deaths caused by all infectious diseases including HIV, TB, and malaria along with malnutrition and perinatal mortality.(3) The burden is not only in human suffering, but it also represents a significant economic burden on societies and health systems; estimates are that a major share of this future burden will occur in developing rather than developed countries. In response to these realities, the United Nations General Assembly has recently adopted a resolution that calls upon nations to address the increasing burden of premature deaths from non-communicable diseases.(4) Moreover, in May 2010 the Assembly voted in favor of convening a special assembly of the UN in 2011 to focus on the prevention and control of chronic diseases. This timely recognition of the importance of chronic diseases creates the opportunity for the respiratory community to demonstrate leadership and focus its attention on key strategies to address chronic respiratory diseases. This leadership was evident with the formation, in 2006, of the Global Alliance against Chronic Respiratory Diseases (GARD); a formal alliance of patient and professional bodies and governments within the WHO with the mandate to promote “a world where all people breathe freely”. GARD has developed a strategic plan and has promoted the enactment of country initiatives, which up-to-date include more than forty. Projects within countries vary, but they share the similar aim of providing a coordinated national approach in addressing the control and management of chronic respiratory diseases and allergies; in most instances these have involved the unprecedented co-operation between different professional societies, with respiratory societies playing a significant leadership role. A further co-operative initiative was the declaration of 2010 as “The Year of the Lung”. This project called on societies to consider ways of focusing communities and
authorities on the need to consider lung health as a priority and has the support of a large number of national and international societies.

As a contribution to this international effort in the Year of the Lung, the Global Initiative for Asthma (GINA), a founding member of GARD, which over almost two decades has provided leadership in asthma through its development, maintenance and promotion of an updated guide on standards of care, embarked on the GINA Asthma Challenge.(5-7) Launched in May 2010, the GINA Asthma Challenge aims at reducing hospitalizations due to asthma by 50% over the next five years. The challenge is directed to countries and foresees co-coordinated planning and implementation of simple, but effective measures to reduce the burden of asthma, using rates of hospital admissions for asthma as the primary marker of success. This approach is not only timely considering the growing recognition of the need for intersectoral co-operation and involvement in addressing public health problems, as exemplified in the formation of GARD, but also the outstanding success, particularly in reducing asthma morbidity reported from countries like Finland that have adopted this approach. In this and other examples, improvements in care have not only been cost-effective, but have also reduced the overall cost of asthma care, which makes them attractive to health ministries and funders.

Hospitalizations have been selected as the main outcome measure in this campaign, as they are not only feared and perceived as a major inconvenience to patients, but are associated with mortality and are a significant driver of healthcare costs.(8) Moreover, they are also highly responsive to interventions and decrease as access to care and controller treatment is improved. It is now widely accepted that the best way to achieve asthma control is through inhaled anti-inflammatory therapy and asthma education.(9-10) The GINA Asthma Challenge goal of a 50% reduction in asthma hospitalizations for each country or region might be perceived as ambitious, but it must be noted that it is based upon experience in a range of national settings. Historically, this has been achieved in higher income countries through the co-ordination of access to a uniform package of care involving education, pharmacotherapy, and follow-up. Reductions in hospitalizations of
up to 68% have been reported. (6) Because this level of care for asthma is currently the exception, most countries should be able, with little additional expenditure, to achieve similar results. In lower income countries, the greatest challenge is to achieve the recognition of asthma as a major health need by health authorities and clinicians and to secure provision of medications for asthma.

Since its formation, advocacy on behalf of patients with asthma has been a major activity of GINA, with many notable successes. It is hoped that the GINA Asthma Challenge will enhance this activity and succeed in countries where asthma is either overlooked or ignored. However, in most of the lower-income nations, the greatest limitation is access to regular supplies of the most effective controller medication for asthma; inhaled corticosteroids. Recently the International Union against Tuberculosis and Lung Diseases established an Asthma Drug Facility, which is able to assist poorer countries with the procurement of asthma medications within the constraints of their meager budgets. (11) To date, several countries have utilized this service.

Besides advocacy and access to asthma drugs, the implementation of evidence-based guidelines is likely to be one of the priorities identified by the UN Special Assembly Meeting in September 2011. (12) As for other chronic diseases, the introduction and uptake of best practice guidelines has, over the last two decades, been associated with great improvements in the management and control of asthma. (13) This timely recognition by the UN to call a special Assembly Meeting in 2011 focusing on chronic diseases provides an opportunity for the respiratory community to take a lead for better management of respiratory diseases both in primary care and hospital settings.
References:


The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJPGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence.

**Potential conflicts of interest:** All authors’ are members of the GINA Executive and all authors except SSH have received honoraria from various pharmaceutical companies for asthma related research and also members of speaker’s bureaux.

**Author affiliations:**

Eric Bateman: Professor of Respiratory Medicine, University of Cape Town, Department of Medicine, Observatory, Cape Town, South Africa. Eric.bateman@uct.ac.za

Suzanne S. Hurd, Ph.D., Scientific Director GINA, Vancouver Washington USA. hurdles1839@comcast.net

Tari Haahtela: Skin and Allergy Hospital, PO Box 160, 00029 HUS, Helsinki University Hospital, Finland.

Tari.Haahtela@hus.fi
Louis-Philippe Boulet: Professor of Medicine, Université Laval, Institut universitaire de cardiologie et de pneumologie de Québec Québec, QC Canada
lpboulet@med.ulaval.ca

Alvaro A. Cruz  Associate Professor of Medicine, ProAR - Federal University of Bahia School of Medicine, Salvador, Brasil.
acruz@ufba.br

Mark Levy: Part time Senior Clinical Research Fellow, Primary Care Research & Development Division of Community Health Sciences: GP Section University of Edinburgh.
mark-levy@btconnect.com